• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sangamo Therapeutics (NQ: SGMO )

    0.3583 -0.0403 (-10.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 20,221,130
    Open 0.4071
    Bid (Size) 0.3710 (100)
    Ask (Size) 0.3800 (22)
    Prev. Close 0.3986
    Today's Range 0.3526 - 0.4200
    52wk Range 0.2911 - 1.670
    Shares Outstanding 145,337,046
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
    Via Benzinga
    SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024
    SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -35.59%
    -35.59%
    1 Month
    -34.28%
    -34.28%
    3 Month
    -41.03%
    -41.03%
    6 Month
    -35.59%
    -35.59%
    1 Year
    -72.44%
    -72.44%

    More News

    Read More
    Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    4 Analysts Assess Sangamo Therapeutics: What You Need To Know
    Via Benzinga
    Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Where Sangamo Therapeutics Stands With Analysts
    Via Benzinga
    Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
    Via Benzinga
    Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Earnings Scheduled For March 13, 2024
    Via Benzinga
    Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    2 low-priced gene therapy stocks to speculate on
    Via MarketBeat
    Exposures Product Safety
    Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.